Amgen's cholesterol-lowering antibody Repatha is being launched in Europe at well below the new drug's cost in the US, raising the chance that American payers will seek hefty discounts on the drug.

Amgen's cholesterol drug Repatha has been given the green light in Europe, making it the first in the new PCSK9 inhibitor class approved anywhere in the world. Repatha (evolocumab) is a human ...

Leqvio (inclisiran) and Repatha (evelocumab) are prescription injectable medications used to treat high cholesterol. They specifically target low-density lipoprotein cholesterol (LDL-C), or "bad ...

It’s not known whether Repatha (evolocumab) is safe to use while pregnant or breastfeeding. Certain factors may determine whether you should use the drug during this time. It’s not known ...

High cholesterol treatment Repatha vaulted higher with a 36% increase over 2023 to more than $1.6 billion. In pure dollar terms, the company's champion was osteoporosis drug Prolia, with its ...

[Repatha package insert;9a] When PCSK9 is inactivated or inhibited, the LDL receptor/LDL cholesterol (LDL-C) particle complex is still internalized by endocytosis; however, once in the cell ...

However, the expected decline in Repatha pricing and potential revenue pressure from loss of patent exclusivity present hurdles. Amgen's current share price shows a slight discount, approximately ...